Advertisement
Research Article| Volume 378, P187-192, July 15, 2017

Brain positron emission tomography in patients with myotonic dystrophy type 1 and type 2

      Highlight

      • Study included 29 patients (16 DM1 and 13 DM2).
      • Executive and naming dysfunction were found.
      • FDG-PET showed glucose hypometabolism in prefrontal, temporal, and pericentral regions.
      • PET findings corresponded well with the results of neuropsychological testing.

      Abstract

      Aim

      To determine regions of reduced brain metabolism in patients with myotonic dystrophy type 1 (DM1) and type 2 (DM2) using 18F-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET), and to analyse their potential association with cognitive deficit.

      Method

      Study included 29 patients (16 DM1 and 13 DM2). FDG-PET and detailed neuropsychological testing were performed in both groups.

      Results

      The most common cognitive findings were executive, visuospatial, and naming dysfunction in DM1, and executive and naming dysfunction in DM2. FDG-PET showed the most prominent glucose hypometabolism in prefrontal, temporal, and pericentral regions in both DM1 and DM2 patients, with additional affection of insula and subcortical grey matter in DM2. In DM1 patients, we found association between right frontotemporal hypometabolism and executive dysfunction (p < 0.05). In DM2 patients attention deficit was in association with prefrontal, insular, and striatal hypometabolism, as well as right frontotemporal hypometabolism (p < 0.05). Executive dysfunction in DM2 was more common in patients with prefrontal and insular hypometabolism, right parietotemporal and frontotemporal hypometabolism, as well as left striatal hypometabolism (p < 0.05). Patients with parietotemporal defect on FDG-PET were more likely to have naming dysfunction (p < 0.01).

      Conclusion

      FDG-PET findings corresponded well with the results of neuropsychological testing. FDG-PET may be a good biomarker of central nervous system involvement in DM1 and DM2, but this hypothesis will have to be more strongly supported by larger studies.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of the Neurological Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Harper P.S.
        • Monckton D.G.
        Myotonic dystrophy.
        in: Engel A.G. Franzini-Armstrong C. Myology. third ed. McGraw-Hill, New York2004: 1039-1076
        • Turner C.
        • Hilton-Jones D.
        Myotonic dystrophy: diagnosis, management and new therapies.
        Curr. Opin. Neurol. 2014; 27: 599-606
        • Meola G.
        • Sansone V.
        Cerebral involvement in myotonic dystrophies.
        Muscle Nerve. 2007; 36: 294-306
        • Minnerop M.
        • Weber B.
        • Schoene-Bake J.C.
        • et al.
        The brain in myotonic dystrophy 1 and 2: evidence for a predominant white matter disease.
        Brain. 2011; 134: 3530-3546
        • Meola G.
        • Sansone V.
        • Perani D.
        • et al.
        Executive dysfunction and avoidant personality trait in myotonic dystrophy type 1 (DM-1) and in proximal myotonic myopathy (PROMM/DM-2).
        Neuromuscul. Disord. 2003; 3: 813-821
      1. Vielhaber S, Jakubiczka S, Gaul C, et al. Brain 1H magnetic resonance spectroscopic differences in myotonic dystrophy type 2 and type 1. Muscle Nerve 2006; 34:145–152.

        • Modoni A.
        • Silvestri G.
        • Pomponi M.G.
        • Mangiola F.
        • Tonali P.A.
        • Marra C.
        Characterization of the pattern of cognitive impairment in myotonic dystrophy type 1.
        Arch. Neurol. 2004; 61: 1943-1947
        • Weber Y.G.
        • Roebling R.
        • Kassubek J.
        • et al.
        Comparative analysis of brain structure, metabolism, and cognition in myotonic dystrophy 1 and 2.
        Neurology. 2010; 74: 1108-1117
        • Romeo V.
        • Pegoraro E.
        • Squarzanti F.
        • et al.
        Retrospective study on PET-SPECT imaging in a large cohort of myotonic dystrophy type 1 patients.
        Neurol. Sci. 2010; 31: 757-763
        • Meola G.
        • Sansone V.
        • Perani D.
        • et al.
        Reduced cerebral blood flow and impaired visual-spatial function in proximal myotonic myopathy.
        Neurology. 1999; 53: 1042-1050.3
        • Sansone V.
        • Gandossini S.
        • Cotelli M.
        • et al.
        Cognitive impairment in adult myotonic dystrophies: a longitudinal study.
        Neurol. Sci. 2007; 28: 9-15
        • Peric S.
        • Pavlovic A.
        • Ralic V.
        • et al.
        Transcranial sonography in patients with myotonic dystrophy type 1.
        Muscle Nerve. 2014; 50: 278-282
        • Caso F.
        • Agosta F.
        • Peric S.
        • Rakocevic-Stojanovic V.
        • Copetti M.
        • Kostic V.S.
        • et al.
        Cognitive impairment in myotonic dystrophy type 1 is associated with white matter damage.
        PLoS One. 2014; 9: e1046974
        • Schneider-Gold C.
        • Bellenberg B.
        • Prehn C.
        • et al.
        Cortical and subcortical Grey and white matter atrophy in myotonic dystrophies type 1 and 2 is associated with cognitive impairment, depression and daytime sleepiness.
        PLoS One. 2015; 10: e0130352
        • Serra L.
        • Mancini M.
        • Silvestri G.
        • et al.
        Brain connectomics' modification to clarify motor and nonmotor features of myotonic dystrophy type 1.
        Neural. Plast. 2016; 2016: 2696085
        • Fiorelli M.
        • Duboc D.
        • Mazoyer B.M.
        • et al.
        Decreased cerebral glucose utilization in myotonic dystrophy.
        Neurology. 1992; 42: 91-94
        • Annane D.
        • Fiorelli M.
        • Mazoyer B.
        • et al.
        Impaired cerebral glucose metabolism in myotonic dystrophy: a triplet-size dependent phenomenon.
        Neuromuscul. Disord. 1998; 8: 3945
        • Renard D.
        • Collombier L.
        • Castelli C.
        • et al.
        In myotonic dystrophy type 1 reduced FDG-uptake on FDG-PET is most severe in Brodmann area 8.
        BMC Neurol. 2016; 16: 100
        • Chang L.
        • Anderson T.
        • Migneco O.A.
        • et al.
        Cerebral abnormalities in myotonic dystrophy. Cerebral blood flow, magnetic resonance imaging, and neuropsychological tests.
        Arch. Neurol. 1993; 50: 917-923
        • Pavlovic D.
        Dijagnosticki testovi u neuropsihologiji.
        second ed. Grafos, Beograd2003
        • Geffen G.
        • Hoar K.J.
        • O'Hanlon A.P.
        • Clark C.R.
        • Geffen L.B.
        Performance measures of 16- to 86-year-old males and females on the Auditory Verbal Learning Test.
        Clin. Neuropsychol. 1990; 4: 45-63
        • Spreen O.
        • Strauss E.
        A Compendium of Neuropsychological Tests. Administration, Norms and Commentary.
        Oxford University Press, New York1991
        • Goodglass H.
        • Kaplan E.
        The Assessment of Aphasia and Related Disorders.
        Lea and Febiger, Philadelphia1983
        • Varrone A.
        • Asenbaum S.
        • Vander Borght T.
        • et al.
        EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2.
        Eur. J. Nucl. Med. Mol. Imaging. 2009; 36: 2103-2110
      2. INLAB Web service - http://inlab.ibfm.cnr.it/inlab/SPM.php

        • Meola G.
        Clinical aspects, molecular pathomechanisms and management of myotonic dystrophies.
        Acta Myol. 2013; 32: 154-165
        • Peric S.
        • Mandic-Stojmenovic G.
        • Stefanova E.
        • Savic-Pavicevic D.
        • Pesovic J.
        • Ilic V.
        • Dobricic V.
        • Basta I.
        • Lavrnic D.
        • Rakocevic-Stojanovic V.
        Frontostriatal dysexecutive syndrome: a core cognitive feature of myotonic dystrophy type 2.
        J. Neurol. 2015; 262: 142-148
        • Winblad S.
        • Lindberg C.
        • Hansen S.
        Cognitive deficits and CTG repeat expansion size in classical myotonic dystrophy type 1 (DM1).
        Behav. Brain Funct. 2006; 2: 16
        • Serra L.
        • Silvestri G.
        • Petrucci A.
        • et al.
        Abnormal functional brain connectivity and personality traits in myotonic dystrophy type 1.
        JAMA Neurol. 2014; 71: 603-611
        • Modoni A.
        • Silvestri G.
        • Vita M.G.
        • et al.
        Cognitive impairment in myotonic dystrophy type 1 (DM1): a longitudinal follow-up study.
        J. Neurol. 2008; 255: 1737-1742
        • Winblad S.
        • Samuelsson L.
        • Lindberg C.
        • et al.
        Cognition in myotonic dystrophy type 1: a 5-year follow-up study.
        Eur. J. Neurol. 2016; 23: 1471-1476
        • Sansone V.
        • Meola G.
        • Perani D.
        • et al.
        Glucose metabolism and dopamine PET correlates in a patient with myotonic dystrophy type 2 and parkinsonism.
        J. Neurol. Neurosurg. Psychiatry. 2006; 77: 425-426
        • Chu K.
        • Cho J.W.
        • Song E.C.
        • Jeon B.S.
        A patient with proximal myotonic myopathy and parkinsonism.
        Can. J. Neurol. Sci. 2002; 29: 188-190
        • Wunderlich S.
        • Csoti I.
        • Reiners K.
        • Günthner-Lengsfeld T.
        • Schneider C.
        • Becker G.
        • Naumann M.
        Camptocormia in Parkinson's disease mimicked by focal myositis of the paraspinal muscles.
        Mov. Disord. 2002; 17: 598-600
        • Rakocevic Stojanovic V.
        • Peric S.
        • Paunic T.
        • et al.
        Quality of life in patients with myotonic dystrophy type 2.
        J. Neurol. Sci. 2016; 365: 158-161
        • Annane D.
        • Fiorelli M.
        • Mazoyer B.
        • et al.
        Impaired cerebral glucose metabolism in myotonic dystrophy: a triplet-size dependent phenomenon.
        Neuromuscul. Disord. 1998; 8: 39-45